Correspondence

Should Patients With Interstitial Lung Disease Be Seen by Experts?

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: V. C. has received fees for speaking, participated as member of steering committee, investigator to clinical trials, and serving in advisory boards from Actelion, Bayer, Boehringer Ingelheim, Galapagos, GSK, Intermune, MSD, Novartis, and Roche. D. C. has received personal fees from Roche and Boehringer-Ingelheim, outside the submitted work. V. P. has received fees for speaking, and participated as member of steering committee, investigator to clinical trials, and served in advisory boards from Boehringer Ingelheim, Erbe, InterMune, and Roche. M. K. has received grants and personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Galapagos, and grants and personal fees from Roche/InterMune, outside the submitted work. T. J. C. has received fees for speaking, participated as member of steering committee, investigator to clinical trials, and served in advisory boards from Roche; fees for advisory board and speakers fees from Boehringer Ingelheim; fees for advisory board from Astra Zeneca; and an institution unrestricted educational grant for research from Intermune, Bayer, BMS, and Actelion. P. S. has received personal fees and nonfinancial support from Roche, Boehringer-Ingelheim, and Zambon, and personal fees from PPM Services and Galapagos.

Editor's Note: Authors are invited to respond to Correspondence that cites their previously published work. Those responses appear after the related letter. In cases where there is no response, the author of the original article declined to respond or did not reply to our invitation.